These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21576452)

  • 1. Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.
    Goldwirt L; Braun J; de Castro N; Charreau I; Barrail-Tran A; Delaugerre C; Raffi F; Lascoux-Combe C; Aboulker JP; Taburet AM; Molina JM
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3613-5. PubMed ID: 21576452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide.
    González de Requena D; Calcagno A; Bonora S; Ladetto L; D'Avolio A; Sciandra M; Siccardi M; Bargiacchi O; Sinicco A; Di Perri G
    AIDS; 2006 Oct; 20(15):1977-9. PubMed ID: 16988521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.
    Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP
    AIDS; 2007 Sep; 21(14):1977-80. PubMed ID: 17721109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide.
    Weizsaecker K; Kurowski M; Hoffmeister B; Schürmann D; Feiterna-Sperling C
    Int J STD AIDS; 2011 May; 22(5):294-5. PubMed ID: 21571982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
    Jackson A; Moyle G; Dickinson L; Back D; Khoo S; Taylor J; Gedela K; Abongomera G; Gazzard B; Boffito M
    Antivir Ther; 2012; 17(1):19-24. PubMed ID: 22267465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Desensitization to tipranavir caused by toxicodermia].
    Martínez Castro B; Ferrando Piqueres R; Martínez García M; Soler Company E
    Farm Hosp; 2009; 33(6):340-2. PubMed ID: 20038397
    [No Abstract]   [Full Text] [Related]  

  • 7. [Role of the new molecules in antiretroviral therapy. Position of raltegravir].
    Arribas JR
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():53-9. PubMed ID: 19572427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
    Jackson A; Watson V; Back D; Khoo S; Liptrott N; Egan D; Gedela K; Higgs C; Abbas R; Gazzard B; Boffito M
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):450-7. PubMed ID: 21926632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
    Langmann P; Winzer R; Schirmer D; Heinz W; Leyh M; Guhl C; Weissbrich B; Klinker H
    Eur J Med Res; 2008 Oct; 13(10):469-71. PubMed ID: 19008174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
    Berhan A; Berhan Y
    PLoS One; 2013; 8(4):e60814. PubMed ID: 23593314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E; Gottlieb MS; Gathe JC; Greenberg ML; Guittari CJ; Zolopa AR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4315-9. PubMed ID: 18809940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
    Belperio PS; Mole LX; Boothroyd DB; Backus LI
    J Manag Care Pharm; 2009 May; 15(4):323-34. PubMed ID: 19422272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
    Calza L; Danese I; Colangeli V; Manfredi R; Magistrelli E; Verucchi G; Conti M; Motta R; Viale P
    Infect Dis (Lond); 2015 Sep; 47(9):625-36. PubMed ID: 25875396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a salvage regimen based on tipranavir, enfuvirtide and three nucleoside analogues in HIV1 infected patients with clinical progression: 96-week evaluation.
    Sozio F; Polilli E; D'Annunzio M; Falconi L; Di Masi F; Tontodonati M; Cosentino L; Consorte A; Di Giammartino D; Parruti G
    Infez Med; 2009 Dec; 17(4):228-35. PubMed ID: 20046103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darunavir offers potent new combo when used with enfuvirtide in ritonavir-boosted regimen.
    Edmunds-Ogbuokiri T
    HIV Clin; 2007; 19(1):1-3. PubMed ID: 17405221
    [No Abstract]   [Full Text] [Related]  

  • 18. A 12-year-old boy with multidrug-resistant human immunodeficiency virus type 1 successfully treated with HAART including ritonavir-boosted tipranavir oral solution and enfuvirtide.
    Feiterna-Sperling C; Walter H; Wahn V; Kleinkauf N
    Eur J Med Res; 2009 Jan; 14(1):44-6. PubMed ID: 19258211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone.
    Bruce RD; Altice FL; Moody DE; Lin SN; Fang WB; Sabo JP; Wruck JM; Piliero PJ; Conner C; Andrews L; Friedland GH
    Drug Alcohol Depend; 2009 Dec; 105(3):234-9. PubMed ID: 19726139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.